Camrelizumab

Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al.
Read more
€0.00 (tax incl.)
Reference:
HY-P9971
Product Details
HY-P9971

Data sheet

Size
Multiple sizes
Reactivity
PD-1/PD-L1
Application
Cancer-programmed cell death
CAS
1798286-48-2

Menu

Settings